Navigation Links
NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
Date:4/28/2011

SAN MATEO, Calif., April 28, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent entitled, "Methods and Compositions for Administration of TRPV1 Agonists."  The allowed claims include method of use, formulation and system claims.  The patent scheduled to issue from this application is expected to expire in 2024, with additional patent term expected in excess of approximately two years due to Patent Term Adjustment.

Anthony DiTonno, President and CEO, commented, "We believe that the Notice of Allowance for our second generation product is very significant and welcome news.  The target product profile for NGX-1998 includes similar efficacy, but a greatly reduced treatment time for NGX-1998 when compared to Qutenza®.  We believe that NGX-1998 has the potential to be a successful product in neuropathic pain, if approved for marketing, and that the granting of this patent will provide us with long-term protection for this product candidate."  

Similar claims have been issued to NeurogesX in a Eurasian patent.  The Company also received a Notice of Allowance in a related Canadian patent application.

Other Recent Patent Issuances

NeurogesX continues to be focused on developing the underlying intellectual property that supports its current and potential future product families, both in the United States and major markets throughout the world.  Since 2009, the Company has been granted patents covering capsaicin-related products such as capsaicin prodrugs, capsaicin oils, a skin cleansing gel and a specific type of capsaicin patch.  Recent patent issuances include the following:  

    '/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
(Date:5/17/2013)...  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) ... Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from ... (NIAID), a division of the National Institutes of ... antibody therapeutics to combat Staphylococcus aureus ... methicillin-resistant S. aureus (MRSA), was renewed ...
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ("Sony") ... Spectral Analyzer (SP6800).  Sony will be exhibiting and taking ... be held at the San Diego ... , from May 20 - 22.  ... system, incorporating commercial audio-visual technologies into new and novel ...
Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2
(Date:5/19/2013)... ATS 2013, PHILADELPHIA ─ Gourmands and foodies everywhere have ... a little peppery zing to both sweet and savory ... shows purified components of the spicy root also may ... , The results of the study will be presented ... characterized by bronchoconstriction, a tightening of the bronchial tubes ...
(Date:5/19/2013)... In partnership with the medical practice online marketing ... of an SEO website for dentists. The purpose of the ... , http://www.e-dentists.com/ , A perk to the service ... they see results. Dentists can request the keywords they want ... JD Media Surge, LLC rank high for competitive keywords. Dentists ...
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... York (PRWEB) May 19, 2013 The ... Case Management Conference was recently convened for hundreds of ... multidistrict litigation now underway in U.S. District Court, Southern ... the Court’s website on May 14th, the Conference addressed ... was also reported during the Conference that Defendants submitted ...
(Date:5/19/2013)... Vegas Hotel Escapes, the premier ... the launch it's all new vacation packages for the ... 5/19/2013. Consumers traveling to Las Vegas will be pleased ... VegasHotelEscapes.com's website. Travelers will be pleased to know that ... , Vegas Hotel Escapes specializes in helping consumers ...
Breaking Medicine News(10 mins):Health News:Ginger compounds may be effective in treating asthma symptoms 2Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3
... with quadriplegia, mutism and lower cranial nerve paralysis ... others is through vertical gaze and upper eyelid ... the June issue of Mayo Clinic Proceedings ... locked-in syndrome who also had dancing eye syndrome ...
... Rare variant may lead immune system to attack healthy ... -- A new study finds that rare gene variations ... the immune system attacks the body. These autoimmune disorders ... report that the findings could lead to better treatments ...
... ... been costly, confusing and time consuming. As a result, nearly 75% of ... all. Nearly half of all resources dedicated to new product development ... consumer packaged goods manufacturers can now launch an investigation of consumer product ...
... Boomers seeking help for drug abuse, study finds , WEDNESDAY, ... older, admissions for drug abuse treatment have nearly doubled between ... cocaine, heroin, prescription drugs, and/or marijuana abuse among men and ... 1992 to just over 12 percent by 2008, according to ...
... limited to the mouth, smokeless tobacco affects the normal ... almost every organ in the body, according to the ... Chemical Research in Toxicology . The enzymes play ... hormones estrogen and testosterone; production of cholesterol and vitamin ...
... disease receive laxatives after being treated with narcotics, despite ... These are the findings from a Nationwide Children,s Hospital ... in Pediatric Blood & Cancer . Narcotic-related ... in hospitalized children and constipation is a frequent narcotic-associated ...
Cached Medicine News:Health News:Mayo Clinic Proceedings: Gabapentin opens window of communication 2Health News:Gene Mutations Offer Clues to Autoimmune Disorders 2Health News:Marketing Research for Companies That Don't Do Marketing Research 2Health News:Marketing Research for Companies That Don't Do Marketing Research 3Health News:'Graying' of Drug Users at U.S. Treatment Centers 2Health News:Sickle cell patients should be better monitored for constipation prevention 2
VerdaSee Dock Door Portal ID solutions provide high performance tracking of assets that enter or leave healthcare facilities through dock doors....
VerdaSee Portal ID is a family of solutions that provide automated tracking and tracing of assets as they enter or leave designated areas within a healthcare facility....
The AeroScout Exciter extends the AeroScout system to provide robust and sophisticated RFID detection capabilities....
... Exit Alerting System, instantly help ... and assets (e.g. medical equipment), ... throughout your facility. With this ... quickly ensured the cost savings, ...
Medicine Products: